Baird Maintains an 'Outperform' on Optimer Pharmaceuticals (OPTR); Analyst Day Takeaways

Baird maintains an 'Outperform' on Optimer Pharmaceuticals (NASDAQ: OPTR) price target of $19.00.

Baird analyst says, "Remain Outperform-rated following uneventful, but informative, analyst day. There was no stock-moving new data, but this was a good check-in on how OPTR is and will continue to build its market for Dificid. While biotech launch stories are not much in favor, we continue to believe this one is trending well versus Q4-11, FY-12, and longer-term expectations. We remain positive on the stock here."

For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.

Shares of Optimer Pharmaceuticals closed at $12.10 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Canaccord Downgrades York Space Systems (YSS) to Hold, 'Supply chain and contract timing uncertainty'
• BofA Securities Starts Definium Therapeutics Inc (DFTX) at Buy
• Freedom Broker Upgrades PrimeEnergy Resource (PNRG) to Hold